drugset
Drugs / pgDC + inactivated whole autologous HIV
last change Feb 2025 re-read 3 minutes ago

pgDC + inactivated whole autologous HIV

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Sharon Riddler

Trials 1

today NCT03758625 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03758625 Jan 2019 → Feb 2025 HIV infectious disease Sharon Riddler Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as pgDC + inactivated whole autologous HIV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03758625 ↗
Modality Vaccine “Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV” NCT03758625 ↗